Cancer clinical trials in the region Grand Est

292 currently recruiting clinical trials
Region Grand Est
Early Access Acute leukemia
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
Excluded genetic anomalies
Ph+ (Philadelphia chromosome positive)
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Amgen
Early Access Lung cancer
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Amgen
Phase 3 Multiple myeloma #NCT07555938 #2025-524028-23-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Monoclonal antibodies Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
7 recruiting sites
Hoffmann-La Roche
Phase 3 Prostate cancer #NCT06629779 #2024-511652-40-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Pfizer
Phase 3 Penile cancer and germ cell tumors #NCT05874063 #2022-502426-41-00
Required histologic types
Germ cell tumor
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required IGCCCG prognostic scores
Good prognosis Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Amyloidosis #NCT07052903 #2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3 Lung cancer #NCT07190248 #2024-514500-14-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT07541170 #2025-524263-21-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Immunotherapy Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Targeted therapy
4 recruiting sites
Hoffmann-La Roche
Phase 3 Lung cancer #NCT06561386 #2024-513682-40-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
NTRK-1/2/3
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
13 recruiting sites
Bristol-Myers Squibb
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT07216703 #2025-521514-26-00
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required CPS scores
CPS Positive (>= 1)
Excluded previous treatments at localized stage
Systemic Treatment-Naive
9 recruiting sites
Merck Sharp & Dohme LLC